α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease - Benskey - 2016 - Journal of Neurochemistry - Wiley Online Library
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Frontiers Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease
Alpha Synuclein in Parkinson's Disease Diagnostics
Frontiers The Role of Lipids in the Initiation of α-Synuclein Misfolding
α-synuclein aggregation assay - Innoprot Parkinson's Disease Models
Novel and rapid device opens new doors for Pa
Stress-induced p53 drives BAG5 cochaperone expression to control α-synuclein aggregation in Parkinson's disease - Figure f6
Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice - Aniszewska - 2022 - Brain and Behavior - Wiley Online Library
p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1
Zeroing in on neurodegenerative α-synuclein
Parkinson's Study Finds New Compound that Can Inhibit Alpha-Synuclein
α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives - Alzghool - 2022 - Movement Disorders - Wiley Online Library
de
por adulto (o preço varia de acordo com o tamanho do grupo)
